CHENGDU, China, 10 de febrero de 2025 /PRNewswire/ — Keymed Biosciences (HKEX: 02162) ha anunciado hoy que la Administración Nacional de Productos Médicos (NMPA) de China ha aprobado recientemente la solicitud de nuevo fármaco complementario (sNDA) de Stapokibart (anticuerpo monoclonal…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.